Research programme: recombinant human insulin - Adocia

Drug Profile

Research programme: recombinant human insulin - Adocia

Alternative Names: BioChaperone Lispro U300; Combo insulin fast and slow - Adocia; insulin glulisine/insulin aspart - Adocia; Ultra-concentrated prandial insulin - Adocia

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adocia
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 27 Jan 2017 Research programme: recombinant human insulin - Adocia is available for licensing as of 27 Jan 2017. http://www.adocia.fr/WP/
  • 27 Jan 2017 Eli Lilly terminated the agreement which was signed in December 2014 with Adocia for the joint development and commercialisation of BioChaperone® Lispro
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in France (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top